Deuruxolitinib, a JAK1/JAK2 inhibitor, is FDA-approved for moderate to severe alopecia areata, marking a significant advancement in treatment options. The THRIVE-AA1 trial showed deuruxolitinib's ...
Dr Saroj Suvanasuthi, M.D., Ph.D., ABHRS, a dermatologist at Samitivej Sukhumvit Hospital and recipient of the “World Cup of Dermoscopy 2018” award in Greece, has highlighted the global rise ...
In this work, we present MedImageInsight, an open-source medical imaging embedding model. MedImageInsight is trained on medical images with associated text and labels across a diverse collection of ...